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 BACKGROUND:  Patients with pulmonary arterial hypertension (PAH) associated with systemic 
sclerosis (SSc-APAH) experience higher mortality rates than patients with idiopathic disease 
and those with other connective tissue diseases (CTD-APAH). We sought to identify unique 
predictors of mortality associated with SSc-APAH in the CTD-APAH population. 
 METHODS:  The Registry to Evaluate Early and Long-Term PAH Management (REVEAL 
Registry) is a multicenter, prospective US-based registry of patients with previously and newly 
diagnosed (enrollment within 90 days of diagnostic right-sided heart catheterization) PAH. 
Cox regression models evaluated all previously identifi ed candidate predictors of mortality in 
the overall REVEAL Registry population to identify signifi cant predictors of mortality in the 
SSc-APAH (n  5 500) vs non-SSc-CTD-APAH (n  5 304) populations. 
 RESULTS:  Th ree-year survival rates in the previously diagnosed and newly diagnosed SSc-
APAH group were 61.4%   2.7% and 51.2%   4.0%, respectively, compared with 80.9%   
2.7% and 76.4%   4.6%, respectively, in the non-SSc-CTD-APAH group ( P  , .001). In multi-
variate analyses, men aged  . 60 years, systolic BP (SBP)   110 mm Hg, 6-min walk distance 
(6MWD)  , 165 m, mean right atrial pressure (mRAP)  . 20 mm Hg within 1 year, and pulmo-
nary vascular resistance (PVR)  . 32 Wood units remained unique predictors of mortality in 
the SSc-APAH group; 6MWD   440 m was protective in the non-SSc-CTD-APAH group, but 
not the SSc-APAH group. 
 CONCLUSIONS:  Patients with SSc-APAH have higher mortality rates than patients with non-
SSc-CTD-APAH . Identifying patients with SSc-APAH who are at a particularly high risk of 
death, including elderly men and patients with low baseline SBP or 6MWD, or markedly ele-
vated mRAP or PVR, will enable physicians to identify patients who may benefi t from closer 
monitoring and more aggressive treatment. 
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 ABBREVIATIONS:  6MWD  5 6-min walk distance; BNP  5 brain natri-
uretic peptide; CTD  5 connective tissue disease; CTD-APAH  5 pul-
monary arterial hypertension associated with connective tissue disease; 
D lco  5 diffusion capacity of the lung for carbon monoxide; FC  5 
functional class; HR  5 hazard ratio; ILD  5 interstitial lung disease; 
IPAH  5 idiopathic pulmonary arterial hypertension; mRAP  5 mean 
right atrial pressure; non-SSc-CTD  5 connective tissue disease other than 
systemic sclerosis; NT-pro-BNP  5 N-terminal-pro-brain natriuretic 
peptide; NYHA  5 New York Heart Association; PAH  5 pulmonary 
arterial hypertension; PVR  5 pulmonary vascular resistance; REVEAL 
Registry  5 Registry to Evaluate Early and Long-Term PAH Management; 
RHC  5 right-sided heart catheterization; SBP  5 systolic BP; SSc  5 systemic 
sclerosis; SSc-APAH  5 pulmonary arterial hypertension associated with 
systemic sclerosis; WHO  5 World Health Organization; WU  5 Wood units 
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 Pulmonary arterial hypertension (PAH) is a rare com-
plication in patients with connective tissue diseases 
(CTDs), and it is associated with high mortality rates, 
particularly in patients with systemic sclerosis (SSc). 1 
Studies have shown that patients with CTD-associated 
PAH (CTD-APAH) experience poorer survival com-
pared with patients with idiopathic PAH (IPAH). 2-4 In 
addition, despite similar baseline hemodynamics, 
patients with PAH associated with SSc (SSc-APAH) 
have the poorest survival rates when compared with 
other CTD-APAH subgroups, including patients with 
systemic lupus erythematosus, mixed CTD, and rheu-
matoid arthritis, in both incident and prevalent 
populations. 3,5 
 Risk score calculators have been developed for patients 
with PAH as a whole, incorporating variables predictive 
of high mortality, including World Health Organization 
(WHO) group 1 subgroup, age, sex, New York Heart 
Association (NYHA) functional class (FC), vital signs, 
6-min walk distance (6MWD), brain natriuretic peptide 
(BNP) level, presence of pericardial eff usion, diff usion 
capacity of the lung for carbon monoxide (D lco ), and 
baseline hemodynamic variables such as mean right 
atrial pressure (mRAP), pulmonary vascular resistance 
(PVR), and cardiac output. 6,7 A study focusing on the 
CTD-APAH population found that higher mRAP, lower 
6MWD, higher FC, and the presence of a pericardial 
eff usion were predictive of death. 8 In contrast, studies 
including patients with SSc-APAH alone have identifi ed 
male sex, lower D lco , older age, and FC IV status as 
independent predictors of death. 9,10 No studies have 
evaluated a large cohort of patients with CTD-APAH 
to identify unique predictors of mortality in patients 
with SSc-APAH. We sought to use the large Registry 
to Evaluate Early and Long-Term PAH Management 
(REVEAL Registry) cohort of patients with CTD-APAH 
to identify unique predictors of mortality in the patients 
with SSc-APAH compared with patients with CTD 
other than SSc (non-SSc-CTD)-APAH that may account 
for the mortality diff erences between these groups. 
 Materials and Methods 
 REVEAL Registry 
 Th e REVEAL Registry is a longitudinal registry involving 54 pulmo-
nary hypertension centers in the United States ( e-Appendix 1 ). Each 
participating center obtained institutional review board approval prior 
to patient enrollment. Th e design and objectives of the REVEAL Registry 
are described elsewhere. 11 All patients provided informed consent prior 
to enrollment, and “enrollment” was defi ned as the date consent was 
given. “Diagnosis” was defi ned as the date of diagnostic right-sided heart 
catheterization (RHC) occurring at or before the date of enrollment. 
Patients with new diagnoses were defi ned as those whose diagnostic RHC 
occurred within 90 days of enrollment. All consecutive patients who, in 
the opinion of the enrolling investigator, had a clinical diagnosis of PAH 
WHO group 1 12 and met the following inclusion criteria were eligible 
for enrollment: (1) mean pulmonary artery pressure of  . 25 mm Hg at 
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rest or 30 mm Hg with exercise, (2) mean pulmonary capillary wedge 
pressure or left ventricular end diastolic pressure of   18 mm Hg, 
(3) PVR of   240 dynes/s/cm 5 (divide by 80 for Wood units [WU]), and 
(4)   3 months of age. 
 Data Collection 
 Th e data in the REVEAL Registry was collected prospectively, but the 
analyses for this study were performed retrospectively. Data collection 
methods have been described previously. 3 Patients were enrolled from 
March 2006 through December 2009. Demographics, clinical char-
acteristics, and outcomes were assessed at enrollment and quarterly 
thereaft er. Th e database of 3,515 patients was locked on February 4, 
2013, for the current analyses. We developed an algorithm ( Fig 1 ) to 
exclude patients with exercise-induced PAH, in accordance with the 
Dana Point Classifi cation Criteria, 12 and those with pulmonary capil-
lary wedge pressure  . 15 mm Hg, who have been shown to diff er in 
many respects from those meeting the traditional hemodynamic defi -
nition of PAH, 13 and included only patients with CTD-APAH. We also 
excluded those with evidence of significant interstitial lung disease 
(ILD), defined as those with evidence of “severe” fibrosis on high-
resolution CT scan of the chest or “moderate” fibrosis if pul monary 
function testing revealed a total lung capacity of  , 60% predicted. 14 
We divided the patients with CTD-APAH into those with SSc-
APAH (SSc group) and those with non-SSc-CTD-APAH (non-SSc 
group). 
 Statistical Analysis 
 Baseline characteristics at the time of enrollment were compared 
between the SSc and non-SSc groups, using the Student  t or Wilcoxon 
test to compare continuous variables and the  x 2 or Fisher exact test 
to compare categorical variables. Because BNP levels were highly 
skewed, the variables were log transformed for comparison as con-
tinuous variables. Cumulative probabilities of survival at 3 years were 
calculated using the Kaplan-Meier estimator for both the previously 
and newly diagnosed populations, and diff erences between the SSc and 
non-SSc groups were compared using the log-rank test. Follow-up 
time was calculated from the date of enrollment. Cox regression models 
identified significant predictors of mortality in the SSc and non-SSc 
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 Figure 1 – STROBE diagram of the 
Registry to Evaluate Early and Long-
Term PAH Management (REVEAL) 
Registry patients used in this 
analysis. We included only patients 
with CTD-APAH who met the strict 
criteria of World Health Organiza-
tion group 1 pulmonary arterial 
hypertension. CTD-APAH  5 
pulmonary arterial hypertension 
associated with connective tissue 
disease; HRCT  5 high-resolution 
CT scan of the chest; ILD  5 
interstitial lung disease; non-SSc-
CTD  5 connective tissue disease 
other than systemic sclerosis; 
PCWP  5 pulmonary capillary 
wedge pressure; SSc  5 systemic 
sclerosis; TLC  5 total lung capacity. 
 Results 
 Baseline Characteristics in Patients 
With CTD-APAH  
 Of 3,515 patients enrolled in the REVEAL Registry, 
815 were identified as having CTD-APAH ( Fig 1 ). 
Of these, 804 (500 SSc and 304 non-SSc) who did not 
have significant ILD were selected for these analyses. 
The majority of patients in the non-SSc group had 
systemic lupus erythematosus-APAH or mixed 
CTD-APAH ( Table 1 ). Patients with SSc were older 
and had a shorter time between diagnostic RHC and 
enrollment into the database than did the patients 
with non-SSc-CTD-APAH ( Table 2 ). Patients with 
SSc-APAH had more severe disease overall, with a 
higher NYHA FC, shorter 6MWD, higher Borg 
dyspnea index, lower D lco , and higher BNP level. 
Patients with SSc-APAH were also more likely to 
have renal insufficiency and pericardial effusions 
than patients with non-SSc-CTD-APAH. Although 
there was a strong trend toward higher mRAP in 
the SSc group, there were no significant differences 
in hemodynamics or PAH-specific therapies at 
the time of enrollment in the SSc vs non-SSc 
groups. 
populations. All variables identifi ed previously as candidate predic-
tors of mortality in the overall REVEAL Registry population were 
evaluated in univariate and multivariate models. Stepwise selection 
was used to determine the fi nal model, retaining only variables with 
 P  , .05. SAS, version 9.1 (SAS Institute Inc) statistical soft ware was 
used for all analyses. 
 TABLE 1 ]  Types of CTD-APAH 
Type of CTD No. (%)
All SSc-APAH 500 (62.2)
SSc, limited 299 (37.2)
SSc, diﬀ use 99 (12.3)
SSc, unknown subtype 102 (12.7)
All non-SSc-CTD-APAH 304 (37.8)
Systemic lupus erythematosus 127 (15.8)
Mixed CTD 71 (8.8)
Rheumatoid arthritis 42 (5.2)
Sjogren syndrome 15 (1.9)
Dermatomyositis/polymyositis 8 (1.0)
Undiﬀ erentiated CTD 12 (1.5)
Overlap syndrome 15 (1.9)
Other 4 (0.5)
Unknown 10 (1.2)
 APAH  5 associated with pulmonary arterial hypertension; CTD  5 
connective tissue disease; non-SSc-CTD  5 connective tissue disease 
other than systemic sclerosis; SSc  5 systemic sclerosis. 
 Poorer Survival in SSc-APAH Compared 
With Non-SSc-CTD-APAH 
 Th ree-year survival in the SSc group was worse than in 
the non-SSc group in both the previously and newly 
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 TABLE 2  ]  Characteristics, Hemodynamics, and Cardiac and Pulmonary Function at Enrollment 
Characteristic SSc-APAH (n  5 500) Non-SSc-CTD-APAH (n  5 304)  P Value
Age at baseline, a y
 No. 500 304 …
 Mean   SD 61.65   11.25 49.88   14.38  , .001
Male sex, No. (%) 63 (12.6) 28 (9.2) .14
Time from diagnostic RHC to enrollment, mo
 No. 500 304 …
 Mean   SD 19.33   23.11 26.72   35.66  , .001
Newly diagnosed, No. (%) 166 (33.2) 88 (28.9) 0.21
NYHA FC, No. (%)  , .0001
 I 15 (3.4) 25 (9.2)
 II 121 (27.8) 105 (38.7)
 III 256 (58.9) 127 (46.9)
 IV 43 (9.9) 14 (5.2)
6MWD, m
 No. 380 248 …
 Mean   SD 294.01   114.6 360.21   122.2  , .001
Heart rate, bpm
 No. 471 287 …
 Mean   SD 84.29   14.94 83.64   14.41 .55
Systolic BP, mm Hg
 No. 477 287 …
 Mean   SD 118.71   18.97 119.28   19.56 .69
Borg dyspnea index
 No. 327 220 …
 Mean   SD 3.67   2.07 3.15   2.28 .005
Renal insuﬃ  ciency, No. (%) 41 (8.4) 9 (3.0) .0024
mRAP, mm Hg
 No. 449 276 …
 Mean   SD 9.04   5.77 8.21   5.06 .052
mPAP at rest, mm Hg
 No. 500 304 …
 Mean   SD 44.59   11.43 45.48   10.67 .27
PCWP at rest, mm Hg
 No. 500 304 …
 Mean   SD 9.11   3.48 8.85   3.48 .29
Cardiac output, b L/min
 No. 499 303 …
 Mean   SD 4.42   1.45 4.28   1.35 .20
Cardiac index, L/min/m 2 
 No. 391 237 …
 Mean   SD 2.50   0.81 2.40   0.75 .11
(Continued)
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Characteristic SSc-APAH (n  5 500) Non-SSc-CTD-APAH (n  5 304)  P Value
PVR, c Wood units
 No. 499 303 …
 Mean   SD 9.31   5.24 9.79   5.34 .21
PVR index, c Wood units  3 m 2 
 No. 391 237 …
 Mean   SD 16.37   9.05 17.36   9.46 .19
FEV 1 , d % predicted
 No. 350 179 …
 Mean   SD 71.93   18.43 73.90   19.20 .25
FVC, d % predicted
 No. 352 181 …
 Mean   SD 74.08   19.22 76.93   20.12 .11
FEV 1 /FVC ratio e 
 No. 374 200 .068
 Mean   SD 0.76   0.09 0.77   0.10 …
D LCO, d % predicted
 No. 344 186 …
 Mean   SD 40.83   16.27 50.36   1 9.00  , .001
Pericardial eﬀ usion, No. (%)
 None 222 (57.1) 159 (68.2) .0090
 Mild 121 (31.1) 62 (26.6) …
 Moderate 36 (9.3) 12 (5.2) …
 Moderate-severe 5 (1.3) 0 (0.0) …
 Severe 5 (1.3) 0 (0.0) …
BNP, pg/mL
 No. 223 154 …
 Mean   SD 562.38   929.9 313.49   685.4 .005
N-terminal BNP, pg/mL
 No. 65 26 …
 Mean   SD 3192.37   4687 932.73   1345 .018
PAH medications at enrollment, No. (%)
 Prostacyclin 154 (31.8) 96 (32.8) .77
 ERA 217 (44.7) 120 (41.0) .30
 PDE-5 inhibitor 223 (46.0) 137 (46.8) .83
 CCB for PAH 42 (8.7) 27 (9.2) .79
PAH medications, No. (%)
 0 90 (18.6) 49 (16.7) .47
 1 231 (47.6) 149 (50.9) …
TABLE 2 ]  (continued)
(Continued)
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diagnosed populations (61.4%   2.7% vs 80.9%   2.7% 
and 51.2%   4.0% vs 76.4%   4.6%, respectively; 
 P  , .001) ( Fig 2 ). 
 Unique Predictors of Mortality in SSc-APAH 
 Figure 3 shows the univariate analyses of previously 
identifi ed predictors of mortality from the overall 
REVEAL Registry cohort in the SSc and non-SSc groups. 
Th e following variables were predictive of mortality in 
both groups: age  . 60 years, NYHA FC III or IV status, 
6MWD  , 165 m, and BNP  . 180 pg/mL. 6MWD   440 m 
was protective in both groups. Unique predictors of mor-
tality in the SSc group, but not the non-SSc group, included 
male sex, systolic BP (SBP)   110 mm Hg, pericardial 
eff usion, D lco   32% predicted, mRAP  . 20 mm Hg 
within 1 year, PVR  . 32 WU, and newly diagnosed 
status. BNP levels  , 50 pg/mL were protective in patients 
with SSc (hazard ratio [HR]  5 0.34; 95% CI, 0.16-0.72; 
 P  5 .005) but not in the non-SSc group (HR  5 0.68; 
95% CI, 0.36-1.29;  P  5 .24).  Figure 3 also shows the 
univariate analyses of additional variables that are rele-
vant to the CTD-APAH population. A higher glomer-
ular fi ltration rate was protective in both groups. Mild 
to moderate ILD was the only feature that increased 
mortality in patients with non-SSc-CTD-APAH but not 
in patients with SSc-APAH (HR  5 2.19; 95% CI, 1.14-4.23; 
 P  5 .02 vs HR  5 0.84; 95% CI, 0.55-1.30;  P  5 .44). When 
compared with IPAH, mRAP  . 20 mm Hg within 
1 year, PVR  . 32 WU, and newly diagnosed status 
remained unique predictors of death in the SSc-APAH 
group. 
 In multivariate analyses, the following variables remained 
predictive of mortality in both the SSc and non-SSc 
groups: NYHA FC III or IV status and BNP  . 180 pg/mL 
( Table 3 ). Unique predictors of mortality in the SSc 
group included men  . 60 years, SBP   110 mm Hg, 
6MWD  , 165 m, mRAP  . 20 mm Hg within 1 year, 
and PVR  . 32 WU. 6MWD   440 m was protective in 
the non-SSc group, but not in the SSc group, whereas 
BNP  , 50 pg/mL was protective in the SSc group, but 
not in the non-SSc group. 
 Discussion 
 Our study provides further evidence that patients with 
SSc-APAH experience higher mortality rates than do 
patients with other CTD-APAH in both incident and 
prevalent populations. Our results validate the useful-
ness of the risk score calculator in patients with CTD-
APAH, including in patients with SSc-APAH. We 
identifi ed several baseline risk factors that were signifi -
cantly associated with mortality in the SSc-APAH popu-
lation in comparison with the non-SSc-CTD-APAH 
population, including being an elderly man, having a 
low SBP, having poor exercise capacity, and having 
severe hemodynamic indices including elevated mRAP 
and PVR. Identifying patients with SSc-APAH with 
high mortality risk based on the presence of these 
unique predictors of mortality will enable physicians 
to monitor these patients more closely and escalate 
therapy when indicated. 
 Th ree-year survival in the newly diagnosed SSc-APAH 
population was 51%, which is similar to survival rates 
found in other cohorts assessed in the modern treat-
ment era. 1,5,9,15,16 Other studies have found better survival 
rates (75%-81%) in patients with SSc-APAH; these rates 
are similar to the survival rate of 77% that we and others 
observed in patients with non-SSc-CTD-APAH. 3,5,10,17,18 
This survival discrepancy could be related to early 
Characteristic SSc-APAH (n  5 500) Non-SSc-CTD-APAH (n  5 304)  P Value
 2 129 (26.6) 81 (27.6) …
 3 35 (7.2) 14 (4.8) …
On combination PAH medications, No. (%) 164 (33.8) 95 (32.4) .69
 P value calculation uses  x 2 test for categorical data or Fisher exact test for categorical data with small cell counts (  5%), and Student  t test for 
continuous data. 6MWD  5 6-min walk distance; BNP  5 brain natriuretic peptide; bpm  5 beats per min; CCB  5 calcium channel blocker; D LCO  5 diﬀ usion 
capacity of the lung for carbon monoxide; ERA  5 endothelin receptor agonist; FC  5 functional class; FCO  5 Fick cardiac output; mPAP  5 mean 
pulmonary arterial pressure; mRAP  5 mean right atrial pressure; NYHA  5 New York Heart Association; PAH  5 pulmonary arterial hypertension; 
PCWP  5 pulmonary capillary wedge pressure; PDE-5  5 phosphodiesterase type-5; PVR  5 pulmonary vascular resistance; RHC  5 right-sided heart 
catheterization. See Table 1 legend for expansion of other abbreviations. 
 a Age  5 (date of informed consent  2 date of birth)/365.25. 
 b Cardiac output  5 FCO, or, if FCO is missing, then cardiac output  5 thermodilution cardiac output. 
 c PVR (Wood units)  5 (mean pulmonary arterial pressure at rest  2 PCWP at rest)/cardiac output, where cardiac output  5 FCO, or, if FCO is missing, then 
cardiac output  5 thermodilution cardiac output. 
 d Predicted value based on Hankinson et al 14 computation. 
 e FEV 1 /FVC ratio is missing if FVC is zero. 
TABLE 2 ]  (continued)
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 Figure 2 – Th ree-year survival 
curves in patients with SSc and 
non-SSc-CTD-APAH. A, Th ree-year 
survival from enrollment in the 
newly diagnosed SSc group was 
51.2%   4.0% compared with 
76.4%   4.6% in the non-SSc-CTD 
group ( P  , .001). B, Th ree-year 
survival from enrollment in the 
previously diagnosed SSc group was 
61.4%   2.7% compared with 
80.9%   2.7% in the non-SSc-CTD 
group ( P  , .001). See  Figure 1 legend 
for expansion of abbreviations. 
detection algorithms that have been implemented in 
these SSc-APAH cohorts, with the goal to initiate PAH-
specifi c therapy when the disease is less severe. Survival 
in patients with non-SSc-CTD-APAH appears to be 
more similar to those with IPAH than to those with 
SSc-APAH, despite similar baseline hemodynamics 
and PAH-specifi c therapies. 3 Whether initiating aggres-
sive PAH treatment in patients with SSc-APAH with a 
particular high mortality risk may improve outcomes 
remains an important question to be answered. 
 Overall, predictors identifi ed in the multivariate model 
in SSc-APAH were very similar to the core predictors 
for PAH as a whole, including all subtypes. 6 Our results 
concur with those of other studies on patients with SSc-
APAH in that male sex, older age, and FC III and IV 
status were signifi cant predictors of death. 5,9,10,15 Our 
results confi rmed those of a single-center study that 
identifi ed high PVR as a strong predictor of mortality. 19 
Unlike these other studies, we did not fi nd that low 
D lco or glomerular fi ltration rate were predictive of 
mortality in the SSc-APAH group in multivariate 
analyses, although they were signifi cant in univariate 
analyses. Lefèvre et al 15 identifi ed additional poor prog-
nostic factors in patients with SSc with pulmonary hyper-
tension in a meta-analysis including patients with WHO 
groups II and III pulmonary hypertension: pericardial 
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 Figure 3 – Predictors of mortality for patients with SSc-APAH and non-SSc-CTD-APAH using univariate Cox regression analyses. Unique predictors 
of mortality in the SSc group, but not the non-SSc group, included male sex, SBP   110 mm Hg, pericardial eff usion, DLCO   32% predicted, 
mRAP  . 20 mm Hg within 1 y, PVR  . 32 WU, and newly diagnosed status. BNP levels  , 50 pg/mL were protective in patients with SSc, but not in the 
non-SSc group. Higher GFR was protective in both groups. Mild to moderate ILD was the only feature that increased mortality in the non-SSc group but 
not in patients with SSc. 6MWD  5 6-min walk distance; BNP  5 brain natriuretic peptide; DLCO  5 diff usion capacity of the lung for carbon monoxide; 
FC  5 functional class; GFR  5 glomerular fi ltration rate; HR  5 hazard ratio; mRAP  5 mean right atrial pressure; NYHA  5 New York Heart Association; 
PVR  5 pulmonary vascular resistance; SBP  5 systolic BP; WHO  5 World Health Organization; WU  5 Wood units. See  Figure 1 legend for expansion of 
other abbreviations. 
eff usion, low 6MWD, high mean pulmonary arterial 
pressure, poor cardiac index, and elevated mRAP were 
poor prognostic factors. Although pericardial eff usion 
lost its signifi cance in our multivariate analysis of 
patients with SSc-APAH, poor exercise capacity and 
elevated mRAP remained significant predictors of 
death. Interestingly, 6MWD  , 165 m was predictive of 
death only in the SSc group, whereas 6MWD   440 m 
was protective only in the non-SSc-CTD-APAH group 
in multivariate analyses. A potential explanation for 
these discrepancies is that patients with SSc can suff er 
from the presence of contractures and tendon friction rubs 
that can signifi cantly limit mobility (particularly those 
with diff use skin disease) in addition to other factors that 
limit exercise capacity (such as anemia and joint or muscle 
infl ammation) in patients with other CTDs. 20,21 However, 
including all variables in the multivariate model without 
stepwise selection, 6MWD  , 165 m was a signifi cant 
predictor of death in the non-SSc group (HR  5 2.03; 
95% CI, 1.01-4.12;  P  5 .05), and 6MWD   440 m showed 
a trend toward a protective eff ect in the SSc group 
(HR  5 0.62; 95% CI, 0.33-1.15;  P  5 .13). In addition, 
when we evaluated the eff ect of 6MWD on mortality 
risk in the various cutaneous subgroups of SSc, an 
increase in distance of 100 m was signifi cantly protec-
tive in all three groups ( P  , .001): diff use HR  5 0.53 
(95% CI, 0.38-0.75); limited 0.59 (95% CI, 0.51-0.68); 
unclassifi ed 0.54 (95% CI, 0.40-0.71 ). 
 In our study, BNP  . 180 pg/mL increased the risk of 
death in both the SSc and non-SSc-APAH groups by 
more than twofold, as has also been shown in patients 
with IPAH. 22 We and others have shown that patients 
with SSc-APAH have markedly elevated BNP and 
N-terminal-pro-BNP (NT-pro-BNP) levels compared 
with patients with IPAH and patients with non-SSc-
CTD-APAH. 3,23 Williams et al 24 found in a UK SSc-
APAH cohort that for every order of magnitude increase 
in baseline NT-pro-BNP level there was a fourfold 
increased risk of death ( P  5 .002). In addition, several 
studies have found that NT-pro-BNP is useful in the 
screening and early detection of PAH in patients with 
SSc, and this biomarker has been integrated into novel 
screening algorithms. 25-27 To our knowledge, our study 
is the fi rst to show that BNP is an independent predictor 
of mortality in patients with CTD-APAH and SSc-
APAH, in particular. Unfortunately NT-pro-BNP levels 
were not available in 89% of our CTD-APAH cohort, 
and, therefore, they could not be included in the regres-
sion models. 
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 TABLE 3  ]  Multivariate Model of Predictors of 
Mortality 
Risk Score Characteristic HR 95% CI  P Value
SSc-APAH
 Men aged  . 60 y 2.222 1.421-3.474  , .001
 NYHA FC III 1.326 1.002-1.756 .049
 NYHA FC IV 2.938 1.921-4.492  , .001
 Systolic 
 BP   110 mm Hg
1.334 1.034-1.723 .027
 6MWD  , 165 m 2.252 1.614-3.142  , .001
 BNP  , 50 pg/mL 0.450 0.209-0.966 .040
 BNP  . 180 pg/mL 2.082 1.617-2.682  , .001
 mRAP  . 20 mm Hg 
 within 1 y
1.910 1.003-3.637 .049
 PVR  . 32 Wood units 14.567 3.464-61.262  , .001
Non-SSc-CTD-APAH
 NYHA FC III 1.679 1.067-2.641 .025
 NYHA FC IV 5.427 2.588-11.383  , .001
 6MWD   440 m 0.293 0.118-0.732 .009
 BNP  . 180 pg/mL 2.466 1.589-3.826  , .001
 HR  5 hazard ratio. See  Table 1 and  2 legends for expansion of other 
abbreviations. 
 To our knowledge, this is the fi rst study to identify low 
baseline SBP   110 mm Hg as an independent predictor 
of death in patients with SSc-APAH. Other studies have 
shown that low SBP, both at peak exercise and upon admis-
sion to the hospital for right-sided heart failure, is an 
independent risk factor for death in PAH. 28,29 A potential 
pathophysiologic explanation for this fi nding is that the 
presence of high right ventricular pressure results in a more 
pronounced eff ect of low SBP on coronary perfusion. Th us, 
low SBP can lead to greater right ventricular dysfunction 
caused by ischemia. In addition, low SBP may be a sign 
of low cardiac output, reduced stroke volume, and neu-
rohormonal activation. 29 Unless complicated by renal 
disease, patients with SSc have relatively low baseline 
BP, 30 and the mean SBP was 119   19 mm Hg in the 
patients with SSc-APAH in our study. Given that BP can 
be monitored easily, identifi cation of low baseline SBP as 
a risk factor in SSc-APAH is an important fi nding. 
 We did not fi nd that mild to moderate ILD was predic-
tive of death in patients with SSc-APAH. Although a 
signifi cant predictor in the non-SSc-APAH group in 
univariate analysis, it was no longer signifi cant in multi-
variate analysis. We attempted to exclude patients with 
substantial ILD as defi ned previously but did not have 
precise measurements regarding the degree of fi brosis 
on imaging. 
 Our study does have some limitations. The SSc-
APAH and non-SSc-CTD-APAH cohorts are smaller 
than the overall cohort. Thus, differences in signifi-
cant multivariable predictors may be caused by loss 
of power as opposed to true differences in predictors 
for different subtypes. In addition, the model does 
not include therapies. Th e majority of REVEAL Registry 
patients, particularly patients who had previous 
diagnoses, were receiving phosphodiesterase-5 inhib-
itors, endothelin receptor antagonists, prostacyclins, 
or a combination. Therefore, the model does not pro-
vide insights into prognosis for untreated patients. 
Although 86% of the patients with CTD-APAH were 
enrolled at sites that routinely involve a rheumatolo-
gist in the diagnosis and care of these patients, mis-
classification of some patients may have occurred. 
Finally, the analysis only assessed variables available 
in the REVEAL Registry database. There may be 
additional factors particular to patients with CTD-
APAH, such as autoantibody status, that could 
impact the results. 
 Conclusions 
 In conclusion, patients with SSc-APAH have higher 
mortality rates than patients with non-SSc-CTD-
APAH. Our results validate the usefulness of the 
PAH risk score in patients with SSc-APAH. We have 
identifi ed unique predictors of mortality in patients 
with SSc-APAH, including being an older man, 
having a low baseline SBP, having poor exercise 
capacity, and having an elevated mRAP and PVR; 
these can be used to identify high-risk patients who 
may benefi t from closer monitoring and more aggres-
sive treatment. 
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